Research being presented at the American Society of Echocardiography’s 33rd Annual Scientific Sessions, June 10-13, 2022, in Seattle, Wash., will share encouraging findings where echocardiography was paramount in showing the effectiveness of a novel drug for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
It wasn’t until the last three years that specific medical therapy existed for hypertrophic cardiomyopathy (HCM)—a condition that causes the heart muscle to thicken and work harder than it should. A recent study examined how a novel cardiac myosin inhibitor drug, known as Aficamten, helped patients suffering from oHCM. Aficamten is one of two cardiac myosin inhibitor drugs currently in various stages of development. Read more here.